![]() |
JOURNAL TOOLS |
Publishing options |
eTOC |
To subscribe PROMO |
Submit an article |
Recommend to your librarian |
ARTICLE TOOLS |
Reprints |
Permissions |
Share |


YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
CASE REPORTS
Minerva Endocrinologica 2012 September;37(3):283-9
Copyright © 2012 EDIZIONI MINERVA MEDICA
language: English
Two-year cyclic infusion of pamidronate improves bone mass density and eliminates risk of fractures in a girl with osteoporosis due to Hajdu-Cheney Syndrome
Galli-Tsinopoulou A. 1, Kyrgios I. 1, Giza S. 1, Giannopoulou E. Z. 1, Maggana I. 1, Laliotis N. 2 ✉
1 .4th Department of Pediatrics, Faculty of Medicine, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Greece; 2 .3rd Department of Orthopedics, Faculty of Medicine, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Greece
Hajdu-Cheney syndrome (HCS) is a rare disorder principally characterized by acro-osteolysis, distinctive craniofacial and skull changes, dental anomalies and short stature. A common finding in HCS patients is secondary osteoporosis that progresses over time and contributes to various skeletal problems, especially fractures. Although autosomal dominant inheritance has been documented in several families, sporadic (non-familial) cases have also been reported. Here, a case of a 9-year-old girl with familial HCS and multiple spinal fractures, who has been effectively treated with pamidronate, is presented. This is the first report of a beneficial effect of intravenous bisphosphonate administration on a child with HCS-related osteoporosis.